Generated by AI
BrainsWay Ltd. Sponsored ADR is a medical technology company focused on non-invasive neurostimulation treatments for brain and mental health disorders. BrainsWay develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) systems, which use magnetic pulses to stimulate targeted brain regions and support treatment for conditions such as major depressive disorder and obsessive-compulsive disorder. The company’s products are used in psychiatric and clinical settings, serving physicians, hospitals, and medical centers that incorporate device-based therapies into patient care. BrainsWay also addresses broader neurological and mental health applications through its commercial treatment platforms and related services. Headquartered in Jerusalem, Israel, BrainsWay operates as a specialized healthcare equipment provider with a focus on advanced brain stimulation technologies and the clinical markets that use them.
Website16 Hartum St
Jerusalem, 9777516
Israel
The latest articles about BWAY.
BrainsWay Ltd (BRSYF) posted $18.1 million in Q3 2026 revenue, doubled operating income to $2.6 million, and signaled full-year results at the high end of guidance on strong SWIFT and OCD demand.
Summary of Mar 11's posts. Generated by AI.
Summary of Aug 29's posts. Generated by AI.
Summary of Aug 29's posts. Generated by AI.
Investors talking about BWAY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.